Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix and Immusol to Collaborate on Cancer Drug Discovery

NEW YORK, June 22 (GenomeWeb News) - Immusol and Affymetrix have signed onto a scientific collaboration in which Immusol will use Affymetrix's gene chips in cancer drug discovery, the companies said today.


Under the collaboration, Immusol, of San Diego, will use Affymetrix's microarrays to conduct gene expression profiling on its engineered tumor cells, and identify pathways related to cancer. The program also aims to "acquire and validate additional therapeutic target candidates," the parties said. The scientists plan to obtain information about the molecular mechanism of actions of drugs or drug targets through perturbing the system and observing the results.


The parties did not disclose the financial terms of the agreement.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.